Related Experiment Video
Updated: May 25, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Antiangiogenic therapy--evolving view based on clinical trial results
Gordon C Jayson1, Daniel J Hicklin, Lee M Ellis
1Department of Medical Oncology, Christie Hospital and University of Manchester, Wilmslow Road, Manchester Academic Health Sciences Centre, Manchester M20 4BX, UK. gordon.jayson@manchester.ac.uk
Nature Reviews. Clinical Oncology
|February 15, 2012
Summary
Targeting VEGF with antiangiogenic therapies shows limited efficacy. Identifying predictive biomarkers, like plasma VEGF-A, is crucial for selecting patients and improving cancer treatment outcomes.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Antiangiogenic therapies targeting Vascular Endothelial Growth Factor (VEGF) are standard cancer treatments.
- Clinical efficacy of VEGF inhibitors is often suboptimal, necessitating combination with chemotherapy.
- Predictive biomarkers are essential for patient selection and maximizing treatment benefit.
Approach:
- Retrospective analysis of plasma VEGF-A concentrations from Phase III trials.
- Evaluation of VEGF-A as a predictive biomarker for bevacizumab efficacy.
- Call for prospective validation and further biomarker research.
Key Points:
- Plasma VEGF-A levels may predict response to bevacizumab in specific cancer types.
- Current antiangiogenic therapy benefits are limited without patient stratification.
- Further biomarker research and high-quality clinical trials are needed.
Conclusions:
- Biomarker-driven patient selection is critical for improving outcomes with VEGF-targeted therapies.
- Prospective validation of VEGF-A assays is required.
- Inter-laboratory collaboration is essential for advancing biomarker research in oncology.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...